* Hb ≥ 100 g/L; absolute leukocyte count ≥ 3.0 x 109 /L; platelets ≥100 x 109 /L
Life expectancy ≥ 12 months.
Swedish or English speaking subjects only.
Written informed consent (subjects must be capable of providing their own informed consent).
You may not be if
Previous ablation of testis.
Radiologic evidence of metastatic disease.
Prior chemotherapy or investigational therapy/agents within 4 weeks.
Active bacterial, viral or fungal infection.
Carrier of HIV, HBV, or HCV.
Immunosuppressed (post splenectomy, post stem cell transplantation) or on immunosuppressive therapy other than inhaled or replacement corticosteroids.
Any other major illness or peripheral blood vein status that, in the investigator's judgement, will substantially increase the risk associated with sampling or participation in this study.
Subjects with cardiac demand pacemakers.
Any reason why, in the opinion of the investigator, the patient should not participate.
Clareo Health | Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer
